However, that there is a precedent for functional and therapeutically actionable EGFR, MET, and BRAF kinase domain duplications in other cancers is suggestive that a similar mechanism may be applicable to the observed RET kinase duplications in breast cancer37–39. The gene discussed is BRAF; the disease is cancer.